181 related articles for article (PubMed ID: 38034491)
1. Lipid-lowering drugs affect lung cancer risk via sphingolipid metabolism: a drug-target Mendelian randomization study.
Li H; Zhang L; Yang F; Feng X; Fu R; Zhao R; Li X; Li H
Front Genet; 2023; 14():1269291. PubMed ID: 38034491
[No Abstract] [Full Text] [Related]
2. Associations of Lipids and Lipid-Lowering Drugs with Risk of Vascular Dementia: A Mendelian Randomization Study.
Zhang X; Geng T; Li N; Wu L; Wang Y; Zheng D; Guo B; Wang B
Nutrients; 2022 Dec; 15(1):. PubMed ID: 36615727
[TBL] [Abstract][Full Text] [Related]
3. Association of genetically predicted lipid traits and lipid-modifying targets with heart failure.
Xiao J; Ji J; Zhang N; Yang X; Chen K; Chen L; Huang W
Eur J Prev Cardiol; 2023 Mar; 30(4):358-366. PubMed ID: 36520639
[TBL] [Abstract][Full Text] [Related]
4. Lipids, lipid-modifying drug target genes and migraine: a Mendelian randomization study.
Bi Y; Zhu Y; Tang S; Huang Y
J Headache Pain; 2023 Aug; 24(1):112. PubMed ID: 37596566
[TBL] [Abstract][Full Text] [Related]
5. Lipids, Apolipoproteins, Statins, and Intracerebral Hemorrhage: A Mendelian Randomization Study.
Yu Z; Zhang L; Zhang G; Xia K; Yang Q; Huang T; Fan D
Ann Neurol; 2022 Sep; 92(3):390-399. PubMed ID: 35655417
[TBL] [Abstract][Full Text] [Related]
6. Association of Triglyceride-Lowering LPL Variants and LDL-C-Lowering LDLR Variants With Risk of Coronary Heart Disease.
Ference BA; Kastelein JJP; Ray KK; Ginsberg HN; Chapman MJ; Packard CJ; Laufs U; Oliver-Williams C; Wood AM; Butterworth AS; Di Angelantonio E; Danesh J; Nicholls SJ; Bhatt DL; Sabatine MS; Catapano AL
JAMA; 2019 Jan; 321(4):364-373. PubMed ID: 30694319
[TBL] [Abstract][Full Text] [Related]
7. Genetically-predicted life-long lowering of low-density lipoprotein cholesterol is associated with decreased frailty: A Mendelian randomization study in UK biobank.
Wang Q; Wang Y; Lehto K; Pedersen NL; Williams DM; Hägg S
EBioMedicine; 2019 Jul; 45():487-494. PubMed ID: 31300347
[TBL] [Abstract][Full Text] [Related]
8. Causal effects of circulating lipids and lipid-lowering drugs on the risk of epilepsy: a two-sample Mendelian randomization study.
Liang Z; Zhao L; Lou Y; Liu S
QJM; 2023 Jun; 116(6):421-428. PubMed ID: 36964718
[TBL] [Abstract][Full Text] [Related]
9. Genetic insights into the association of statin and newer nonstatin drug target genes with human longevity: a Mendelian randomization analysis.
Chen H; Zhou X; Hu J; Li S; Wang Z; Zhu T; Cheng H; Zhang G
Lipids Health Dis; 2023 Dec; 22(1):220. PubMed ID: 38082436
[TBL] [Abstract][Full Text] [Related]
10. Causal effects of lipid-lowering therapies on aging-related outcomes and risk of cancers: a drug-target Mendelian randomization study.
Chen H; Tang X; Su W; Li S; Yang R; Cheng H; Zhang G; Zhou X
Aging (Albany NY); 2023 Dec; 15(24):15228-15242. PubMed ID: 38127052
[TBL] [Abstract][Full Text] [Related]
11. Circulating lipids, lipid-lowering drug targets, and breast cancer risk: Comprehensive evidence from Mendelian randomization and summary data-based Mendelian randomization.
Zhang Z; Zhang D
Cancer Causes Control; 2024 Jun; 35(6):983-994. PubMed ID: 38430374
[TBL] [Abstract][Full Text] [Related]
12. Mendelian randomization study of lipid metabolism characteristics and migraine risk.
Hong P; Han L; Wan Y
Eur J Pain; 2024 Jan; ():. PubMed ID: 38183343
[TBL] [Abstract][Full Text] [Related]
13. Correlations between genetically predicted lipid-lowering drug targets and inflammatory bowel disease.
Huang K; Huang S; Xiong M
Lipids Health Dis; 2024 Jan; 23(1):31. PubMed ID: 38287401
[TBL] [Abstract][Full Text] [Related]
14. Lipids, cholesterols, statins and liver cancer: a Mendelian randomization study.
Liang Z; Zhang Z; Tan X; Zeng P
Front Oncol; 2023; 13():1251873. PubMed ID: 37746259
[TBL] [Abstract][Full Text] [Related]
15. Genetic association of lipid-lowering drug target genes with erectile dysfunction and male reproductive health.
Su Q; Wang R; Luo Y; Tang Q; Wang K
Front Endocrinol (Lausanne); 2024; 15():1362499. PubMed ID: 38390206
[TBL] [Abstract][Full Text] [Related]
16. Genetic association of lipids and lipid-lowering drugs with sepsis: a Mendelian randomization and mediation analysis.
Lou C; Meng Z; Shi YY; Zheng R; Qian SZ; Pan J
Front Cardiovasc Med; 2023; 10():1217922. PubMed ID: 37621565
[TBL] [Abstract][Full Text] [Related]
17. Genetic Association of Lipid-Lowering Drugs with Aortic Aneurysms: A Mendelian Randomization Study.
Gao X; Luo W; Qu L; Yang M; Chen S; Lei L; Yan S; Liang H; Zhang X; Xiao M; Liao Y; Lee AP; Zhou Z; Chen J; Zhang Q; Wang Y; Xiu J
Eur J Prev Cardiol; 2024 Feb; ():. PubMed ID: 38302118
[TBL] [Abstract][Full Text] [Related]
18. Causal Associations of Circulating Lipids with Osteoarthritis: A Bidirectional Mendelian Randomization Study.
Meng H; Jiang L; Song Z; Wang F
Nutrients; 2022 Mar; 14(7):. PubMed ID: 35405941
[TBL] [Abstract][Full Text] [Related]
19. Association of Genetic Variants Related to CETP Inhibitors and Statins With Lipoprotein Levels and Cardiovascular Risk.
Ference BA; Kastelein JJP; Ginsberg HN; Chapman MJ; Nicholls SJ; Ray KK; Packard CJ; Laufs U; Brook RD; Oliver-Williams C; Butterworth AS; Danesh J; Smith GD; Catapano AL; Sabatine MS
JAMA; 2017 Sep; 318(10):947-956. PubMed ID: 28846118
[TBL] [Abstract][Full Text] [Related]
20. Association of lipid-lowering drugs with COVID-19 outcomes from a Mendelian randomization study.
Huang W; Xiao J; Ji J; Chen L
Elife; 2021 Dec; 10():. PubMed ID: 34866576
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
